Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedPublication citation updated: added Lancet Oncology 2025 paper on MIRASOL patient-reported outcomes with an erratum; the previous v3.4.2 citation was removed.SummaryDifference0.0%

- Check30 days agoChange DetectedAdded Fallopian tube cancer as a listed condition on the study page and updated the page revision to v3.4.2.SummaryDifference0.0%

- Check37 days agoChange DetectedMinor site maintenance: Revision: v3.4.1 added and Revision: v3.4.0 removed; no effect on study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedThis update adds a glossary toggle and updates certain metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted) and the revision to v3.4.0, with minor labeling adjustments for No FEAR Act data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check88 days agoChange DetectedLocations section expanded with numerous sites across US states and international regions, detailing where the trial is conducted.SummaryDifference2%

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.